CLINICAL TRIALS PROFILE FOR BREQUINAR
✉ Email this page to a colleague
Clinical Trials for Brequinar
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03760666 ↗ | A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Completed | Clear Creek Bio, Inc. | Phase 1/Phase 2 | A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects. |
| NCT04425252 ↗ | Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19 | Completed | Clear Creek Bio, Inc. | Phase 1/Phase 2 | This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg. |
| NCT04575038 ↗ | CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 | Completed | Clear Creek Bio, Inc. | Phase 2 | This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting. The study is multi-center, randomized, and placebo-controlled. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Brequinar
Condition Name
Clinical Trial Locations for Brequinar
Trials by Country
Clinical Trial Progress for Brequinar
Clinical Trial Phase
Clinical Trial Sponsors for Brequinar
Sponsor Name
